268 related articles for article (PubMed ID: 16541323)
1. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth.
Divisova J; Kuiatse I; Lazard Z; Weiss H; Vreeland F; Hadsell DL; Schiff R; Osborne CK; Lee AV
Breast Cancer Res Treat; 2006 Aug; 98(3):315-27. PubMed ID: 16541323
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy.
Yin D; Vreeland F; Schaaf LJ; Millham R; Duncan BA; Sharma A
Clin Cancer Res; 2007 Feb; 13(3):1000-9. PubMed ID: 17289896
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice.
McCutcheon IE; Flyvbjerg A; Hill H; Li J; Bennett WF; Scarlett JA; Friend KE
J Neurosurg; 2001 Mar; 94(3):487-92. PubMed ID: 11235955
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model.
Evans A; Jamieson SM; Liu DX; Wilson WR; Perry JK
Cancer Lett; 2016 Aug; 379(1):117-23. PubMed ID: 27241667
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone potentiates 17β-estradiol-dependent breast cancer cell proliferation independently of IGF-I receptor signaling.
Felice DL; El-Shennawy L; Zhao S; Lantvit DL; Shen Q; Unterman TG; Swanson SM; Frasor J
Endocrinology; 2013 Sep; 154(9):3219-27. PubMed ID: 23782942
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression.
Minoia M; Gentilin E; Molè D; Rossi M; Filieri C; Tagliati F; Baroni A; Ambrosio MR; degli Uberti E; Zatelli MC
J Clin Endocrinol Metab; 2012 Jun; 97(6):E907-16. PubMed ID: 22442272
[TBL] [Abstract][Full Text] [Related]
7. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.
Veldhuis JD; Bidlingmaier M; Anderson SM; Wu Z; Strasburger CJ
J Clin Endocrinol Metab; 2001 Jul; 86(7):3304-10. PubMed ID: 11443205
[TBL] [Abstract][Full Text] [Related]
8. GH Action in Prostate Cancer Cells Promotes Proliferation, Limits Apoptosis, and Regulates Cancer-related Gene Expression.
Unterberger CJ; Maklakova VI; Lazar M; Arneson PD; Mcilwain SJ; Tsourkas PK; Hu R; Kopchick JJ; Swanson SM; Marker PC
Endocrinology; 2022 May; 163(5):. PubMed ID: 35383352
[TBL] [Abstract][Full Text] [Related]
9. Specific targeting of insulin-like growth factor 1 receptor signaling in human estrogen dependent breast cancer cell by a novel tyrosine-based benzoxazepine derivative.
Chakravarti B; Siddiqui JA; Dwivedi SK; Deshpande S; Samanta K; Bhatta RS; Panda G; Prabhakar YS; Konwar R; Sanyal S; Chattopadhyay N
Mol Cell Endocrinol; 2011 May; 338(1-2):68-78. PubMed ID: 21457754
[TBL] [Abstract][Full Text] [Related]
10. GH receptor blocker administration and muscle-tendon collagen synthesis in humans.
Nielsen RH; Doessing S; Goto K; Holm L; Reitelseder S; Agergaard J; Schjerling P; Flyvberg A; Kjaer M
Growth Horm IGF Res; 2011 Jun; 21(3):140-5. PubMed ID: 21498100
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone receptor antagonists.
Kohn DT; Kopchick JJ
Minerva Endocrinol; 2002 Dec; 27(4):287-98. PubMed ID: 12511851
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
13. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
[TBL] [Abstract][Full Text] [Related]
14. Cancer and the potential place for growth hormone receptor antagonist therapy.
Friend KE
Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S121-3. PubMed ID: 11527083
[TBL] [Abstract][Full Text] [Related]
15. Expression of the growth hormone/insulin-like growth factor axis during Balb/c thymus ontogeny and effects of growth hormone upon ex vivo T cell differentiation.
Kermani H; Goffinet L; Mottet M; Bodart G; Morrhaye G; Dardenne O; Renard C; Overbergh L; Baron F; Beguin Y; Geenen V; Martens HJ
Neuroimmunomodulation; 2012; 19(3):137-47. PubMed ID: 22261974
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications.
Kopchick JJ; List EO; Kelder B; Gosney ES; Berryman DE
Mol Cell Endocrinol; 2014 Apr; 386(1-2):34-45. PubMed ID: 24035867
[TBL] [Abstract][Full Text] [Related]
18. Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance.
Muller AF; Janssen JA; Hofland LJ; Lamberts SW; Bidlingmaier M; Strasburger CJ; van der Lely AJ
J Clin Endocrinol Metab; 2001 Feb; 86(2):590-3. PubMed ID: 11158013
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.
Kleinberg DL; Wood TL; Furth PA; Lee AV
Endocr Rev; 2009 Feb; 30(1):51-74. PubMed ID: 19075184
[TBL] [Abstract][Full Text] [Related]
20. Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome.
Akintoye SO; Kelly MH; Brillante B; Cherman N; Turner S; Butman JA; Robey PG; Collins MT
J Clin Endocrinol Metab; 2006 Aug; 91(8):2960-6. PubMed ID: 16720661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
